Navigation Links
UPDATE - ProUroCare Announces $3 Million Financing Agreement
Date:9/29/2010

$300,000 in 30-day increments.  At each closing, ProUroCare will sell unregistered shares of its common stock to Seaside at a cost that is 50 percent of the stock's volume weighted average selling price during the 10 trading days preceding each closing date, subject to a floor selling price of $1.25 per share below which neither of the parties is obligated to close.  The agreement provides that the closing on any tranche will not occur if it would cause Seaside to beneficially own more than 9.9 percent of ProUroCare's common stock.  They have indicated their willingness to propose an alternative investment vehicle to provide the financing, as they have in other transactions, should a subsequent closing otherwise cause Seaside to exceed this ownership level.  After the first closing, Seaside holds approximately 8.9 percent of ProUroCare's outstanding stock.

"Seaside has demonstrated a longstanding commitment to small and mid-cap companies, allowing them to concentrate on their core competencies and market opportunities.  Their track record of successful investing lends support to the work that has been done by our company in preparing the ProUroScan system for market," said Carlson.  

This transaction was facilitated by Lane Capital Markets of Southport, Conn., which has been engaged to provide ongoing, strategic fundraising and financial advisory support to the company.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a digital rectal examination.

Safe Harbor Statement

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statemen
'/>"/>

SOURCE ProUroCare Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Thousands of people will peacefully demonstrate their frustration ... epidemic at dozens of rallies across the country today. ... the United States has experienced skyrocketing rates ... heroin, yet the President has never once spoken publicly ... to President Obama , rally organizers compared his failure ...
(Date:8/31/2015)... , Aug. 31, 2015  Daktari Diagnostics today announced a ... United States and Canada , ... The deal, worth up to $8.5 million over the next ... clinical validation and regulatory approval of Daktari,s HCV test. ... point-of-care instrument that can detect low levels of virus directly ...
(Date:8/31/2015)... , Aug. 31, 2015 With increasing ... is experiencing a rise in active partnerships. The ... underdeveloped nations to quantitate CD4 cell markers in ... - http://photos.prnewswire.com/prnh/20150831/262206LOGO New ... Global Flow Cytometry Market ( http://www.frost.com/nf0e ), finds ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) ... for routine prevention, pre-procedure prevention and acute treatment ... self administration option for appropriately trained patients included ...
... Texas, June 15, 2011 Two clinical trial studies authored by ... United Network of US Oncology have been selected to be ... July 29-30 in Miami and August 5-6 in Seattle. ... its 47th Annual Meeting June 3-7 at McCormick Place in Chicago. ...
Cached Medicine Technology:ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 2ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 3ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 4ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 5ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 6Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians 2Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians 3Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians 4
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... The dental implant ... according the American Academy of Implant Dentistry. (See Press Room ) More than ... require an implant procedure. With the increasing demand for dental implants, the National Association ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Three Bakers Gluten ... and retailers with even more relevant and easy-to-find information on their offering of gluten-free ... website has always been an important way for us to share information about our ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... 2015 , ... Finnleo is pleased to announce another in a ... of extensive engineering and design of our newest sauna model, the Terrace combines high ... offered at a very attractive price-point. , Before outdoor saunas were a dream ...
Breaking Medicine News(10 mins):Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2
... team up to make food fun,for those with diabetes, ... the daily decisions they make about food can have ... (ADA), together,with The HealthCentral Network,s FoodFit.com, launched Diabetes Foodsmart,today, ... to food for those,with diabetes., Based on the ...
... with 20 percent of all lung malignancies, scientists say ... appear to work together are associated with 20 percent of ... lung development, researchers report. , Understanding how these genes mesh ... according to the report in this week,s issue of the ...
... IRVINE, Calif., Oct. 9 Spectrum,Pharmaceuticals, Inc., (Nasdaq: ... of the Company on Wednesday, October 10, 2007, at ... at the Palace Hotel in San,Francisco, California. Spectrum,s presentation ... live webcast of Spectrum,s presentation will be available at, ...
... Two of the three scientists receiving the 2007 Nobel Prize ... Society early in their careers, bringing to 42 the number ... grantees Mario R. Capecchi, Ph.D. of the University of Utah ... are co-winners along with Sir Martin J. Evans of Cardiff ...
... Oct. 9 In light of last week,s,controversy ... seafood for,pregnant women and the announcement from private ... least 12 ounces of fish,and seafood a week, ... in the natural products sector, suggests that private ...
... Roaming Across ... Campuses in North Carolina, RESTON, Virginia, October 9 ... (RTLS), today announced,that it has been selected as the RTLS vendor ... system in the,United States. CHS is using the Ekahau RTLS solution ...
Cached Medicine News:Health News:Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter 2Health News:Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter 3Health News:3 New Lung Cancer Genes Identified 2Health News:Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum 2Health News:Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women! 2Health News:Carolinas HealthCare Selects Ekahau for One of Nation's Largest Healthcare System RTLS Deployments 2Health News:Carolinas HealthCare Selects Ekahau for One of Nation's Largest Healthcare System RTLS Deployments 3Health News:Carolinas HealthCare Selects Ekahau for One of Nation's Largest Healthcare System RTLS Deployments 4
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The electrically active helix of CapSureFix Novus lead is designed to extend easily for active fixation and retract for venous passage....
Steroid eluting pacemaker leads...
... family of temporary sensing and pacing leads. ... in temporary pacing leads and improved upon ... use and less traumatic to heart tissue. ... Pacing Lead is designed for temporary atrial ...
Medicine Products: